Canada's QLT has snapped up new drug delivery technology for eye conditions with its $42 million acquisition of ForSight Newco II. The deal also includes $40 million in scheduled milestones for the development and commercialization of the new technology, called "punctual plugs."
"This acquisition is a clear strategic fit. It complements our expertise in ophthalmology, and it supports our goal to expand our pipeline of ocular products," said Bob Butchofsky, president and CEO of QLT.
- see QLT's release
QLT says therapy fails Phase II trial. Report
QLT slashes spending as competition looms. Report
QLT shares drop after eye drug flunks vision-loss trial. Report